Page 85 - Priority Review News Today

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has announced that donanemab met all primary and secondary endpoints for the 6-month primary outcome analysis...

Non-binding agreement in principle reached with HCR on sale of Movantik to extinguish all debt obligations, to facilitate growth Q3/22 Net revenues of $17.6...

/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...

REM-001, a photodynamic therapy for metastatic breast cancer was given Fast Track designation by the US Food and Drug Administration (FDA).

The FDA has accepted for Priority Review the BLA for SRP-9001 (delandistrogene moxeparvovec) for ambulant individuals with DMD.

The Spanish biotech SpliceBio outlines how its technology could widen the range of genetic diseases treatable with gene therapies.

Pfizer, Inc. And Merck & Co., Inc - Notable Market Players in Carbapenem-based Antibiotics Market

/PRNewswire/ -- Guerbet LLC, the US affiliate of Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical...

The FDA has accepted for Priority Review the BLA for TAK-003, an investigational tetravalent dengue vaccine.

/PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy...